Theranostics and radiopharmaceutical therapies are rapidly transforming the medical landscape, and the neuro-oncology community is observing these developments with great interest. In a field characte ...
Journal of Nuclear Medicine October 2025, jnumed.125.270804; DOI: https://doi.org/10.2967/jnumed.125.270804 ...
Journal of Nuclear Medicine October 2025, jnumed.125.270825; DOI: https://doi.org/10.2967/jnumed.125.270825 ...
The development of novel multimodality imaging agents and techniques represents the current frontier of research in the field of medical imaging science. However, the combination of nuclear tomography ...
Journal of Nuclear Medicine September 2025, jnumed.125.270267; DOI: https://doi.org/10.2967/jnumed.125.270267 ...
PSMA-targeted radiopharmaceutical therapy (RPT) is a standard treatment for metastatic castration-resistant prostate cancer (PCa), exploiting PSMA overexpression to deliver cytotoxic radiation.
Journal of Nuclear Medicine September 2025, jnumed.125.270391; DOI: https://doi.org/10.2967/jnumed.125.270391 ...
Giri et al. present a case report involving a patient with metachronous low-volume metastatic hormone-sensitive prostate cancer (mHSPC) who declined standard treatments such as androgen deprivation ...
Journal of Nuclear Medicine October 2025, jnumed.125.269840; DOI: https://doi.org/10.2967/jnumed.125.269840 ...
Journal of Nuclear Medicine October 2025, jnumed.124.269188; DOI: https://doi.org/10.2967/jnumed.124.269188 ...
Journal of Nuclear Medicine September 2025, jnumed.124.268809; DOI: https://doi.org/10.2967/jnumed.124.268809 ...
Targeting tumors with antibody-based therapeutics is a complex task presenting multiple kinetic barriers. Antibody internalization and clearance inhibit uptake both in solid tumors, limited by tumor ...